What it sells
MOGLU, a needle-free wearable continuous glucose monitor using Raman spectroscopy; the site reports 11.34% MARD with 100% of readings in Parkes zones A/B in an IRB-approved study with MIT.
Business model breakdown
Trigger: what makes them buy now?
Diabetes patients wanting to avoid needle sensors; June 1 2026 peer-reviewed MIT study (JDST) claims accuracy comparable to FDA-cleared Abbott and Dexcom devices.
Workflow: what inputs become what output?
Wearable (target 40x30x16 mm) uses band-pass Raman spectroscopy to read glucose non-invasively instead of a needle-based sensor.
Economics: what it saves and how it charges
UnverifiedPre-revenue device developer; value rests on a consumer wearable CGM replacing needle-based sensors (not stated on site).
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-09-23 | Series A | KRW 5B | — | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.